Business
ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.
ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President..
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n\n Ft. Lauderdale, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) (\"ETST\" or \"the Company\"), an innovative biotech company focused on hemp cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices; has announced that its wholly owned subsidiary, Earth Science Pharmaceutical, Inc., has initiated a clinical prelaunch study for its MSN-2 medical device for the diagnosis of Chlamydia and Gonorrhea in women. The study will involve 60 female patients. The company has also announced that it has elected Dr. Michel Aubé as its new CEO and CSO (Chief Scientific Officer), as well as Nickolas Tabraue as President of both Earth Science Tech, Inc., and its wholly-owned subsidiary Earth Science Pharmaceutical, Inc. \n This news follows the company’s August 24, 2016 announcement, “ETST Acquired the Assets and Business of BEO-ITS, Inc., a Canadian Biotech Company Specializing in Medical Devices, Tests and Vaccines for Sexually Transmitted Infections and/or Diseases.” This asset purchase agreement of BEO ITS, Inc., which was incorporated under ETST’s new wholly-owned subsidiary, Earth Science Pharmaceutical, Inc., included the employment of its CEO and principal owner, Dr. Aubé as its CEO.  “I’m honored and thrilled to be the CEO and CSO of both Earth Science Tech, Inc., and Earth Science Pharmaceutical, Inc., a company focused on the development of medical devices, testing processes, and vaccines for STIs (Sexually Transmitted Infections and/or Diseases).” stated Dr. Aubé. “I am also excited to announce that Earth Science Pharmaceutical has opened a clinical prelaunch study of its MSN-2 medical device for the diagnosis of Chlamydia and Gonorrhea which will allow us to acquire the final data we need to launch the product. I have personally been working with epidemiologist Dr. Lauren Azoulay on this new study, which will involve recruiting 20 women with Chlamydia and 40 women with Gonorrhea from private medical clinics for testing with our new MSN-2 medical device. The protocol, developed by Dr. Azoulay, will allow all physicians to understand the scope and the value of the new device. The protocol, with the results and the analyzed data, will be transmitted to the authorities once finished. This st...